Yellow Fever (ICD-11: 1D47) - Complete Coding and Diagnostic Guide

1. Introduction

Yellow fever represents one of the most relevant arboviruses in contemporary tropical medicine and infectious diseases. It is an acute viral disease caused by a flavivirus transmitted by mosquitoes, capable of causing presentations ranging from self-limited febrile illness to severe hepatic failure with fatal hemorrhagic manifestations. The name "yellow" derives from the characteristic jaundice that affects patients in the more severe forms of the disease.

This condition maintains significant importance in global public health, particularly in tropical regions of Africa and South America, where Aedes and Haemagogus vectors find ideal conditions for proliferation. Yellow fever presents two distinct epidemiological cycles: the sylvatic, which occurs in forested areas involving non-human primates as reservoirs, and the urban, which involves transmission between humans in densely populated areas.

The correct coding of this disease in the ICD-11 system is fundamental for effective epidemiological surveillance, planning of vaccination campaigns, adequate allocation of public health resources, and outbreak monitoring. The code 1D47 allows precise case tracking, analysis of geographic and temporal trends, and facilitates international comparative studies on the disease. Health professionals must understand not only the clinical aspects of yellow fever, but also the specific criteria that justify the use of this diagnostic code, differentiating it from other arboviruses with similar clinical presentations.

2. Correct ICD-11 Code

Code: 1D47

Description: Yellow fever

Parent category: Some viral fevers transmitted by arthropods

Official definition: Condition caused by an infection with the yellow fever virus. This condition is characterized by fever, chills, headache, myalgia, conjunctival congestion or relative bradycardia. Severe conditions may also manifest with increased fever, jaundice, renal insufficiency or bleeding. Transmission is through the bite of an infected mosquito. Confirmation is made by detection of anti-yellow fever virus IgM antibodies in a serum sample.

Code 1D47 belongs to the chapter of infectious and parasitic diseases, specifically to the group of viral fevers transmitted by arthropods. This classification reflects the mechanism of vector transmission and groups yellow fever together with other clinically relevant arboviruses. The hierarchical structure of ICD-11 facilitates navigation between related codes and allows for clearer understanding of the relationships between different vector-transmitted conditions. The absence of subcategories for code 1D47 indicates that the classification does not subdivide yellow fever into specific subtypes within the system, although clinically we recognize different forms of severity and clinical presentations.

3. When to Use This Code

Code 1D47 should be applied in specific clinical situations that meet the diagnostic criteria for yellow fever:

Scenario 1: Patient with acute febrile illness post-exposure in endemic area An unvaccinated patient develops high fever with sudden onset, intense headache, generalized myalgias, and conjunctival congestion three to six days after visiting a forest area known for sylvatic yellow fever transmission. Serology demonstrates the presence of IgM antibodies specific to yellow fever virus. This classic clinical scenario fully justifies the use of code 1D47.

Scenario 2: Severe form with classic triad Patient presents with characteristic biphasic evolution: after an initial period of fever, headache, and myalgias, develops progressive jaundice, oliguria with elevated serum creatinine, and hemorrhagic manifestations (hematemesis, melena, epistaxis). Laboratory tests confirm significant elevation of transaminases and bilirubin, with detection of viral RNA by PCR or specific IgM antibodies. This severe presentation with hepatorenal involvement and hemorrhagic manifestations is coded as 1D47.

Scenario 3: Confirmed case during epidemiological outbreak During investigation of an outbreak in an area with confirmed yellow fever cases, patient develops acute febrile syndrome with relative bradycardia (Faget's sign), retro-orbital headache, and intense lower back myalgia. Even with milder symptomatology, laboratory confirmation by IgM detection or viral isolation justifies coding 1D47, being fundamental for epidemiological surveillance.

Scenario 4: Post-mortem diagnosis Patient rapidly progressed to death with fever, jaundice, and hemorrhages. Histopathological analysis of liver tissue obtained by biopsy or autopsy reveals characteristic hepatocellular necrosis with Councilman bodies and absence of significant inflammatory infiltrate. Immunohistochemistry or PCR in tissue confirms the presence of yellow fever virus. Code 1D47 is appropriate even in retrospective diagnosis.

Scenario 5: Laboratory-confirmed oligosymptomatic form Patient with history of exposure in a risk area develops low-grade fever, mild headache, and malaise for three to four days, with spontaneous resolution. Serological investigation performed according to surveillance protocol detects seroconversion with specific IgM antibodies. Despite the attenuated presentation, laboratory confirmation indicates viral infection and justifies code 1D47.

Scenario 6: Reactivation in immunocompromised patient Previously vaccinated patient, but under severe immunosuppression, develops a clinical picture compatible with yellow fever. Molecular investigation detects vaccine virus with evidence of active replication. Although rare, this specific scenario also uses code 1D47, and should be complemented with additional codes that identify the underlying immunosuppressive condition.

4. When NOT to Use This Code

It is essential to recognize situations where code 1D47 is not appropriate, avoiding diagnostic confusion:

Adverse reactions to yellow fever vaccine: Adverse events following vaccination, including fever, myalgias, or even neurological manifestations (vaccine-associated viscerotropic or neurotropic disease), should not be coded as 1D47. These cases require specific codes for vaccine complications or adverse drug reactions.

Other arboviruses with similar presentation: Dengue, Chikungunya, and Zika may present with fever, headache, myalgias, and even hemorrhagic manifestations. Coding as 1D47 is only appropriate with specific laboratory confirmation for yellow fever. The presence of diffuse maculopapular rash, common in dengue and Zika, is less characteristic of yellow fever.

Viral hepatitis of other etiologies: Jaundice with elevated transaminases may occur in hepatitis A, B, C, E, or due to cytomegalovirus and Epstein-Barr virus. Yellow fever should be differentiated through compatible epidemiological history and specific serological confirmation. Classic viral hepatitis rarely presents with such prominent hemorrhagic manifestations.

Leptospirosis: This bacterial zoonosis can mimic yellow fever with fever, jaundice, renal insufficiency, and hemorrhagic manifestations (Weil's syndrome). Differentiation requires specific laboratory investigation including serology or PCR for Leptospira and exclusion of yellow fever.

Severe malaria: Especially due to Plasmodium falciparum, it may present with high fever, jaundice, and renal impairment. Plasmodium screening on blood smear is essential for differentiation. History of antimalarial prophylaxis use and fever pattern also aid in distinction.

Nonspecific febrile syndrome without confirmation: Acute febrile conditions in endemic areas, without specific laboratory confirmation for yellow fever, should not receive code 1D47. In these cases, codes for nonspecific febrile syndrome are more appropriate until diagnostic definition.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Appropriate coding begins with rigorous diagnostic confirmation. The diagnosis of yellow fever is based on clinical, epidemiological, and laboratory criteria. Clinically, seek the presence of fever with sudden onset (usually above 38°C), intense headache, generalized myalgias, nausea, vomiting, and conjunctival congestion. Relative bradycardia (Faget's sign) is a valuable finding when present.

Carefully evaluate the epidemiological history: exposure in a known endemic area, activities in wild environments, absence of previous vaccination or vaccination more than ten years ago. The typical incubation period of three to six days after exposure is relevant information.

In severe cases, identify manifestations of the toxic phase: progressive jaundice, oliguria, elevated creatinine, hemorrhagic manifestations (gingival bleeding, epistaxis, hematemesis, melena, ecchymoses), altered level of consciousness. Laboratory findings should show significant elevation of transaminases (frequently above 1000 U/L), hyperbilirubinemia with predominance of direct bilirubin, prolonged prothrombin time, thrombocytopenia.

Laboratory confirmation is essential: detection of specific IgM antibodies by ELISA (most common method), viral isolation in cell culture, detection of viral RNA by RT-PCR, or detection of viral antigens in tissues by immunohistochemistry. At least one of these methods must be positive to justify definitive coding.

Step 2: Verify specifiers

Although code 1D47 does not present formal subcategories in ICD-11, adequately document severity and clinical characteristics. Classify as mild form (constitutional symptoms without jaundice or organ dysfunction), moderate form (more intense symptoms but without organ failure) or severe form (presence of jaundice, renal insufficiency, hemorrhagic manifestations, altered consciousness).

Record the disease phase: infection period (first three days with viremia), remission period (when applicable, with transient improvement of symptoms) or intoxication period (toxic phase with hepatorenal involvement). This temporal characterization aids in prognosis and clinical management.

Identify the epidemiological cycle involved: sylvatic yellow fever (exposure in forest environments) or urban (transmission in urban areas, currently rare but of great epidemiological importance). Document whether the case is autochthonous or imported, information crucial for epidemiological surveillance.

Step 3: Differentiate from other codes

1D40 - Chikungunya virus disease: The main difference lies in the intense arthralgia and polyarthritis characteristic of Chikungunya, frequently disabling and with possibility of chronicity. Jaundice and severe hemorrhagic manifestations are rare in Chikungunya. Maculopapular exanthem is more common. Specific serological confirmation is determinant.

1D41 - Colorado tick fever: This arbovirus transmitted by ticks (not mosquitoes) occurs in specific mountainous regions. It is characterized by biphasic fever with "saddle-back" pattern, leukopenia and thrombocytopenia, but rarely progresses with jaundice or renal insufficiency. History of tick bite and specific geographic exposure are important differentials.

1D42 - O'nyong-nyong fever: African arbovirus transmitted by Anopheles mosquitoes, presents with fever, arthralgia, lymphadenopathy, and exanthem. Does not progress with jaundice or severe hemorrhagic manifestations. Polyarthritis can be prolonged, similar to Chikungunya. Geographic distribution restricted to East Africa and specific serological confirmation are key differentials.

Step 4: Required documentation

For appropriate coding of 1D47, ensure that the medical record contains:

Mandatory checklist:

Date of symptom onset and duration
Detailed description of symptoms (fever, headache, myalgias, jaundice, hemorrhages)
Complete epidemiological history (exposure in endemic area, risk activities, travel dates)
Vaccination status against yellow fever (dates of previous doses)
Physical examination with vital signs, including heart rate and temperature
Laboratory results: complete blood count, liver function, renal function, coagulation profile
Confirmatory tests: IgM serology, PCR, viral isolation or immunohistochemistry
Clinical evolution and complications when present
Treatment instituted and therapeutic response
Notification to health authorities (mandatory)

Clearly record which laboratory method confirmed the diagnosis and when it was performed, considering that IgM can be detected from the fifth day of symptoms and persists for months.

6. Complete Practical Example

Clinical Case:

A 42-year-old male patient, farmer, admitted to the emergency department with a history of high fever (39.5°C) starting four days ago, accompanied by intense frontal headache, retro-orbital pain, generalized myalgias (particularly in the lumbar region), nausea and vomiting. Reports that ten days ago he performed deforestation work in a rural area near a forest fragment, with the presence of monkeys in the region. Denies previous yellow fever vaccination.

On physical examination: patient in fair general condition, febrile (38.8°C), heart rate 68 bpm (relative bradycardia for the degree of fever), blood pressure 110/70 mmHg. Evident bilateral conjunctival congestion. Mucous membranes slightly pale. Absence of jaundice at the time of admission. Abdomen with mild pain on palpation in the right hypochondrium, liver palpable 2 cm below the right costal margin.

Initial tests: hemoglobin 13.5 g/dL, leukocytes 3,200/mm³ with lymphopenia, platelets 98,000/mm³, AST 420 U/L, ALT 380 U/L, total bilirubin 2.1 mg/dL (direct 1.4 mg/dL), creatinine 1.3 mg/dL, prothrombin time with INR 1.4.

On the third day of hospitalization, the patient presented clinical deterioration with development of progressive jaundice, oliguria (urine output 300 mL/24h), epistaxis and gingival bleeding. New tests: AST 2,800 U/L, ALT 2,400 U/L, total bilirubin 12.8 mg/dL (direct 9.2 mg/dL), creatinine 3.8 mg/dL, platelets 45,000/mm³, INR 2.8.

Serology for yellow fever (ELISA IgM) collected on the fourth day of symptoms returned positive. PCR for yellow fever virus also detected viral RNA. Serologies for dengue, hepatitis A, B and C were negative.

Step-by-Step Coding:

Criteria Analysis:

Clinical criteria met: Fever of sudden onset, intense headache, myalgias, conjunctival congestion, relative bradycardia (Faget sign present). Progression to severe form with jaundice, renal insufficiency and hemorrhagic manifestations.
Epidemiological criteria met: Exposure in rural area with presence of primates (natural reservoirs), deforestation activity with exposure to vector mosquitoes, absence of previous vaccination.
Laboratory criteria met: Confirmation by two methods (positive IgM serology and positive PCR). Laboratory alterations compatible with severe hepatorenal involvement.
Exclusion of differential diagnoses: Negative serologies for other viral hepatitis and dengue. Clinical and laboratory pattern characteristic of yellow fever.

Code chosen: 1D47 - Yellow fever

Complete justification:

The code 1D47 is fully justified in this case by the presence of all essential diagnostic criteria. The clinical presentation exhibits the cardinal elements of yellow fever: acute febrile syndrome with headache, myalgias and conjunctival congestion, followed by progression to severe form with jaundice, renal insufficiency and hemorrhagic manifestations. The epidemiological history is highly suggestive, with exposure in a sylvatic environment and absence of immunization. Unequivocal laboratory confirmation by two independent methods (serology and molecular biology) solidifies the diagnosis.

The biphasic evolution, although not clearly documented in this case, and the presence of Faget sign are valuable clinical findings. The laboratory pattern with marked elevation of transaminases, hyperbilirubinemia with direct predominance, coagulopathy and renal insufficiency is characteristic of the severe form of the disease.

Applicable complementary codes:

Code for acute renal insufficiency (to document specific complication)
Code for hemorrhagic manifestations (when there is a need to specify complications)
Procedure code: intensive care unit support, if applicable
Code for compulsory notification to health authorities

This case illustrates the importance of early recognition and adequate laboratory confirmation for correct coding, as well as highlighting the need for rigorous epidemiological surveillance in cases of yellow fever.

7. Related Codes and Differentiation

Within the Same Category:

1D40: Chikungunya virus disease

When to use vs. 1D47: Use 1D40 when the patient presents with acute fever with intense and disabling arthralgia, frequently polyarticular and symmetric, affecting mainly small joints of the hands, wrists, ankles and feet. Maculopapular rash is common, usually appearing between the second and fifth day of illness.

Main difference: Chikungunya is characterized by severe and frequently prolonged arthralgia (potentially becoming chronic in 30-40% of cases), whereas yellow fever is distinguished by the potential for progression to jaundice, hepatorenal insufficiency and severe hemorrhagic manifestations. Specific serological confirmation for each virus is determinant. Chikungunya rarely causes jaundice or significant hepatic involvement.

1D41: Colorado tick fever

When to use vs. 1D47: Apply 1D41 when there is a clear history of tick bite in specific mountainous regions (mainly North America), with development of characteristic biphasic fever in a "saddle" pattern - fever for 2-3 days, remission for 1-2 days, followed by febrile recrudescence.

Main difference: The vector is a tick (not a mosquito), the geographic distribution is restricted, the biphasic fever pattern is more consistent, and progression to jaundice or renal insufficiency is extremely rare. Leukopenia and thrombocytopenia are common, but significant hepatocellular involvement does not occur. Specific laboratory confirmation and epidemiological context are distinctive.

1D42: O'nyong-nyong fever

When to use vs. 1D47: Code as 1D42 when the patient presents with fever with polyarthritis, generalized lymphadenopathy and pruritic rash, with history of exposure in East Africa (restricted geographic distribution).

Main difference: O'nyong-nyong presents prominent lymphadenopathy and pruritic rash as distinctive features, with arthralgia that may persist for weeks. It does not progress with jaundice, renal insufficiency or severe hemorrhagic manifestations. The vectors are Anopheles mosquitoes (different from yellow fever vectors). Geographic restriction to East Africa and specific serological confirmation are determinant.

Differential Diagnoses:

Dengue: May present with fever, headache, myalgias and even hemorrhagic manifestations (severe dengue). It differs by the frequent presence of rash, more intense retro-orbital pain, positive tourniquet test, and absence of significant jaundice. Specific serological confirmation is essential.

Leptospirosis: May mimic yellow fever with jaundice, renal insufficiency and hemorrhages. It differs by history of exposure to contaminated water, presence of conjunctival suffusion (not just congestion), calf pain, and confirmation by serology or PCR specific for Leptospira.

P. falciparum malaria: May cause jaundice and renal insufficiency. It differs by the fever pattern in paroxysms, more prominent splenomegaly, and confirmation by plasmodium research on blood smear. History of exposure in malaria endemic area is relevant.

8. Differences with ICD-10

Equivalent ICD-10 code: A95 - Yellow fever (with subdivisions A95.0 for sylvatic yellow fever and A95.1 for urban yellow fever)

Main changes in ICD-11:

The transition from ICD-10 to ICD-11 brought important structural simplification. In ICD-10, yellow fever was subdivided into sylvatic (A95.0) and urban (A95.1), reflecting the two distinct epidemiological cycles. ICD-11 unifies these presentations under the single code 1D47, eliminating the need to formally distinguish between epidemiological cycles in coding.

This change reflects the understanding that, although transmission cycles are epidemiologically distinct, the disease caused by the virus is identical from a clinical and pathological standpoint. The distinction between sylvatic and urban cycles remains relevant for epidemiological surveillance and vector control, but does not justify separate codes in the classification system.

ICD-11 also incorporated more detailed and precise definition, explicitly stating specific diagnostic criteria such as relative bradycardia and laboratory confirmation methods. The modified alphanumeric structure (1D47 versus A95) reflects broader reorganization of the classification system, facilitating future expansion and better grouping of related conditions.

Practical impact of these changes:

For professionals accustomed to ICD-10, the main adaptation is using a single code regardless of transmission cycle, maintaining the sylvatic/urban distinction only in clinical and epidemiological documentation, not in formal coding. Epidemiological surveillance systems may require additional fields to capture this information when relevant for outbreak analysis and vector control planning.

The more detailed definition in ICD-11 facilitates standardization of diagnostic criteria among different services and countries, potentially improving comparability of international epidemiological data. Professionals should familiarize themselves with the new alphanumeric structure for efficient navigation in the system.

9. Frequently Asked Questions

How is a definitive diagnosis of yellow fever made?

Definitive diagnosis requires specific laboratory confirmation. The most common method is detection of IgM antibodies against yellow fever virus by ELISA, which becomes positive from the fifth day of symptoms and can persist for months. Detection of viral RNA by RT-PCR is possible in the early days of disease (viremia period), being highly specific. Viral isolation in cell culture is confirmatory but technically complex and time-consuming. In fatal cases, immunohistochemistry in liver tissue can detect viral antigens. It is essential to exclude other causes of icteric febrile syndrome, particularly other viral hepatitis and leptospirosis.

Is there specific treatment available for yellow fever?

There is no specific antiviral treatment against yellow fever virus. Management is exclusively supportive, focusing on maintenance of vital functions and treatment of complications. In mild forms, outpatient treatment with hydration, antipyretics (avoiding salicylates due to hemorrhagic risk) and rest is sufficient. Severe forms require hospital admission, often in an intensive care unit, with rigorous monitoring of renal and hepatic function, correction of hydroelectrolytic and acid-base disturbances, ventilatory support when necessary, and management of hemorrhagic complications. Hemodialysis may be necessary in severe renal failure. Adequate and early supportive treatment can significantly reduce mortality.

Is vaccination effective in prevention and what is the coverage in public health systems?

Yellow fever vaccine is highly effective, conferring protective immunity in more than 95% of vaccinated individuals within 10 days after administration of a single dose. Immunity is considered durable, potentially for life, although some countries still recommend a booster dose after 10 years for travelers to high-risk areas. The vaccine is widely available in public health systems of countries where the disease is endemic, often being included in national vaccination schedules. For international travelers, vaccination may be required for entry into certain countries and should be performed at authorized centers that issue the International Certificate of Vaccination. Contraindications include severe immunosuppression, allergy to vaccine components, and age under 6 months.

How long does the disease last and what period of absence from work is necessary?

The duration of yellow fever varies according to severity. Mild forms generally present with symptoms for 3 to 4 days, with complete recovery in 1 to 2 weeks. Severe forms may have a more prolonged course, with hospitalization period of 2 to 4 weeks or more, depending on complications. The viremia period (when the patient can infect mosquitoes) is short, generally limited to the first 3 to 5 days of symptoms. Absence from work activities should consider severity: mild cases can return after symptom resolution and recovery of general condition (usually 1 to 2 weeks); severe cases require prolonged absence until complete recovery of organ function, which may take months. Patients should avoid mosquito exposure during the febrile period to prevent transmission.

Can this code be used in medical certificates and occupational documentation?

Yes, code 1D47 can and should be used in official medical documentation, including medical certificates and reports for occupational or social security purposes. Yellow fever is a disease of mandatory immediate notification, and proper documentation is fundamental for both the patient and epidemiological surveillance. In certificates, one may choose to include the ICD-11 code 1D47 or simply describe "viral infectious disease" if there is concern about patient privacy, although specification is generally appropriate. For purposes of prolonged work absence or social security benefits, detailed documentation with the specific code facilitates analysis of medical expert evaluations. Remember that notification to health authorities is mandatory and independent of the documentation provided to the patient.

What are the warning signs that indicate progression to severe form?

Warning signs indicating possible progression to severe form include: persistence or recrudescence of fever after 3 days, development of jaundice (yellowish discoloration of skin and mucous membranes), oliguria (reduction in urine output), hemorrhagic manifestations (gingival bleeding, epistaxis, hematemesis, melena, spontaneous ecchymoses), intense abdominal pain particularly in the right hypochondrium, persistent vomiting, arterial hypotension, altered level of consciousness (drowsiness, confusion, agitation). Laboratorially, progressive elevation of transaminases (especially above 1000 U/L), increasing hyperbilirubinemia, elevation of creatinine, prolongation of prothrombin time, and marked thrombocytopenia are indicators of severity. Patients with these signs require immediate hospitalization and intensive monitoring.

Is there risk of person-to-person transmission?

No, yellow fever is not transmitted directly from person to person. Transmission mandatorily requires an intermediate vector (mosquito). The transmission cycle involves: infected person → mosquito that bites during viremia period → infected mosquito after extrinsic incubation period → new susceptible person bitten by the infected mosquito. Therefore, there is no need for contact isolation of the patient, but it is important to protect him from mosquito bites during the febrile period (first 5 days) to prevent him from serving as a source of infection for vectors, especially in areas with presence of Aedes aegypti (potential for urban transmission). Healthcare professionals do not require special personal protective equipment beyond standard precautions. There is no risk of transmission through contact with secretions or body fluids.

How to differentiate yellow fever from dengue in the initial phase?

In the initial phase, clinical differentiation between yellow fever and dengue can be challenging, as both present with high fever, headache, myalgias and malaise. Some elements help: conjunctival congestion is more characteristic of yellow fever, while intense retro-orbital pain and rash are more common in dengue. Relative bradycardia (Faget's sign) when present suggests yellow fever. Epidemiological context is crucial: history of exposure in a sylvatic area and absence of vaccination favor yellow fever; urban outbreaks of febrile exanthematous disease suggest dengue. Clinical evolution also differs: significant jaundice, marked elevation of transaminases (>1000 U/L) and renal failure are more characteristic of severe yellow fever; severe dengue is characterized by plasma extravasation, hemoconcentration and shock. Specific laboratory confirmation by serology or PCR is essential for definitive diagnosis, and both should be investigated simultaneously in suspected cases.

Conclusion:

Proper coding of yellow fever using ICD-11 code 1D47 requires integrated understanding of the clinical, epidemiological and laboratory aspects of this important arbovirus. Healthcare professionals should be alert to specific diagnostic criteria, the need for laboratory confirmation, and careful differentiation from other conditions with similar presentation. Accurate documentation and immediate notification to health authorities are essential components of proper management, contributing to effective epidemiological surveillance and outbreak control. Vaccination remains the most effective preventive measure, and early recognition of severity signs can be determinant for the prognosis of affected patients.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Yellow fever

Share